MX2020003049A - Semaglutida en la terapia medica. - Google Patents
Semaglutida en la terapia medica.Info
- Publication number
- MX2020003049A MX2020003049A MX2020003049A MX2020003049A MX2020003049A MX 2020003049 A MX2020003049 A MX 2020003049A MX 2020003049 A MX2020003049 A MX 2020003049A MX 2020003049 A MX2020003049 A MX 2020003049A MX 2020003049 A MX2020003049 A MX 2020003049A
- Authority
- MX
- Mexico
- Prior art keywords
- semaglutide
- medical therapy
- therapy
- medical
- relates
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17196254 | 2017-10-12 | ||
| PCT/EP2018/077654 WO2019072941A1 (en) | 2017-10-12 | 2018-10-10 | SEMAGLUTIDE IN MEDICAL THERAPY |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020003049A true MX2020003049A (es) | 2020-07-27 |
Family
ID=60083831
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020003049A MX2020003049A (es) | 2017-10-12 | 2018-10-10 | Semaglutida en la terapia medica. |
| MX2025002189A MX2025002189A (es) | 2017-10-12 | 2020-03-19 | Semaglutida en la terapia medica |
| MX2025002188A MX2025002188A (es) | 2017-10-12 | 2020-03-19 | Semaglutida en la terapia medica |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2025002189A MX2025002189A (es) | 2017-10-12 | 2020-03-19 | Semaglutida en la terapia medica |
| MX2025002188A MX2025002188A (es) | 2017-10-12 | 2020-03-19 | Semaglutida en la terapia medica |
Country Status (18)
| Country | Link |
|---|---|
| US (5) | US12029779B2 (enExample) |
| EP (1) | EP3694538A1 (enExample) |
| JP (2) | JP7148605B2 (enExample) |
| KR (1) | KR20200069316A (enExample) |
| CN (4) | CN120241968A (enExample) |
| AU (2) | AU2018348929B2 (enExample) |
| BR (1) | BR112020006246A2 (enExample) |
| CA (1) | CA3078652A1 (enExample) |
| CL (1) | CL2020000812A1 (enExample) |
| IL (3) | IL322969A (enExample) |
| MA (1) | MA50358A (enExample) |
| MX (3) | MX2020003049A (enExample) |
| MY (1) | MY204827A (enExample) |
| PH (1) | PH12020550185A1 (enExample) |
| SG (1) | SG11202002841PA (enExample) |
| TW (1) | TWI842681B (enExample) |
| WO (1) | WO2019072941A1 (enExample) |
| ZA (3) | ZA202503388B (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3078652A1 (en) * | 2017-10-12 | 2019-04-18 | Novo Nordisk A/S | Semaglutide in medical therapy |
| US12605426B2 (en) | 2020-02-14 | 2026-04-21 | G2Gbio, Inc. | Pharmaceutical comprising sustained-release microspheres including GLP-1 analogue or pharmaceutically acceptable salt thereof |
| IL294521A (en) | 2020-02-18 | 2022-09-01 | Novo Nordisk As | glp-1 compounds and their uses |
| US11478533B2 (en) * | 2020-04-27 | 2022-10-25 | Novo Nordisk A/S | Semaglutide for use in medicine |
| WO2022212271A1 (en) * | 2021-03-29 | 2022-10-06 | Sanford Health | Methods and compositions for treating lysosomal storage disorders |
| AU2023285400A1 (en) * | 2022-06-08 | 2024-12-05 | Zydus Lifesciences Limited | Reusable multi-dose, variable dose, single pen injector for type 2 diabetes and weight management |
| WO2024249659A2 (en) * | 2023-05-30 | 2024-12-05 | The Medical College Of Wisconsin, Inc. | Methods for weight loss and/or reducing weight gain |
| US12597496B2 (en) * | 2023-06-05 | 2026-04-07 | Closed Loop Medicine Ltd. | Dosing of incretin pathway drugs |
| US20260007869A1 (en) | 2023-06-23 | 2026-01-08 | Vaxess Technologies, Inc. | Microneedle array patches (maps), systems, and methods for manufacturing and using same |
| US20260199436A1 (en) * | 2025-01-16 | 2026-07-16 | Novo Nordisk A/S | Semaglutide in medical therapy including weight management |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6268343B1 (en) | 1996-08-30 | 2001-07-31 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
| ES2298378T3 (es) | 2001-06-28 | 2008-05-16 | Novo Nordisk A/S | Formulacion estable de glp-1 modificado. |
| EP1670515A2 (en) | 2003-09-19 | 2006-06-21 | Novo Nordisk A/S | Albumin-binding derivatives of therapeutic peptides |
| KR101243648B1 (ko) | 2003-11-20 | 2013-03-14 | 노보 노르디스크 에이/에스 | 제조 및 주사 장치용에 최적인 프로필렌 글리콜 함유펩티드 제제 |
| RU2413530C9 (ru) | 2004-11-12 | 2021-05-18 | Ново Нордиск А/С | Стабильные препараты инсулинотропных пептидов |
| TWI362392B (en) | 2005-03-18 | 2012-04-21 | Novo Nordisk As | Acylated glp-1 compounds |
| MX373000B (es) | 2005-09-14 | 2020-05-21 | Mannkind Corp | Metodo para formulacion de farmaco basado en el aumento de la afinidad de agentes activos hacia las superficies de microparticulas cristalinas. |
| RU2409349C2 (ru) | 2006-04-14 | 2011-01-20 | Маннкайнд Корпорейшн | Фармацевтические композиции, содержащие глюкагонподобный пептид(glp-1) |
| DK2481410T3 (en) | 2007-01-31 | 2016-10-24 | Bial - Portela & Ca S A | Nitrocatecholderivater as COMT inhibitors administered in a specific dosage regimen |
| EP2121897A4 (en) | 2007-03-20 | 2010-03-31 | Nippon Kayaku Kk | METHOD FOR MONITORING THE DRUG EFFECT ON DIABETES PATIENTS USING AN ASSAY FOR 1,5-ANHYDRO-D-GLUCITOL |
| US20100292133A1 (en) | 2007-09-05 | 2010-11-18 | Novo Nordisk A/S | Truncated glp-1 derivaties and their therapeutical use |
| HUE031900T2 (en) | 2008-12-10 | 2017-08-28 | Glaxosmithkline Llc | Pharmaceutical compositions containing Albiglutide |
| WO2010092163A2 (en) | 2009-02-13 | 2010-08-19 | Boehringer Ingelheim International Gmbh | Antidiabetic medications |
| US20120329711A1 (en) | 2009-12-16 | 2012-12-27 | Nordisk A/S | Glp-1 receptor agonist compounds with a modified n-terminus |
| MX341025B (es) * | 2010-05-05 | 2016-08-04 | Boehringer Ingelheim Int Gmbh * | Terapia de combinacion. |
| CN102203130B (zh) | 2010-08-06 | 2014-06-25 | 贝达药业股份有限公司 | Glp-1衍生物及其应用 |
| MX377589B (es) | 2010-12-16 | 2025-03-10 | Novo Nordisk As | Composiciones sólidas que comprenden agonista de glp-1 y sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico. |
| RU2013133803A (ru) | 2010-12-22 | 2015-01-27 | Маркадиа Байотек, Инк. | Способы лечения метаболических нарушений и ожирения при помощи пептидов на основе глюкагона, активных по отношению к рецепторам гип и гпп |
| US20130035281A1 (en) | 2011-02-09 | 2013-02-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| CN102718858B (zh) | 2011-03-29 | 2014-07-02 | 天津药物研究院 | 胰高血糖素样肽-1类似物单体、二聚体及其制备方法与应用 |
| WO2012136790A1 (en) | 2011-04-07 | 2012-10-11 | Glaxo Group Limited | Compositions comprising fusion proteins or conjugates with an improved half -life |
| UA116189C2 (uk) | 2011-05-02 | 2018-02-26 | Мілленніум Фармасьютікалз, Інк. | КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА |
| CN102229668A (zh) | 2011-06-03 | 2011-11-02 | 浙江贝达药业有限公司 | 一种glp-1衍生物及其应用 |
| US20140220134A1 (en) | 2011-06-24 | 2014-08-07 | Astrazeneca Pharamceuticals LP | Method for treating diabetes with extended release formulation of glp-1 receptor agonists |
| SI2753312T1 (sl) | 2011-09-08 | 2017-10-30 | Mereo Biopharma 2 Limited | Uporaba inhibitorja aromataze za zdravljenje hipogonadizma in sororodnih bolezni |
| EP2846823B1 (en) | 2012-05-08 | 2019-12-04 | Novo Nordisk A/S | Double-acylated glp-1 derivatives |
| US9603826B2 (en) | 2012-06-29 | 2017-03-28 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
| HUE049152T2 (hu) * | 2012-07-01 | 2020-09-28 | Novo Nordisk As | Hosszantartó hatású GLP-1 peptidek alkalmazása |
| RS58039B1 (sr) * | 2013-05-02 | 2019-02-28 | Novo Nordisk As | Oralno doziranje glp-1 jedinjenja |
| CN117106085A (zh) | 2015-12-23 | 2023-11-24 | 美国安进公司 | 使用gipr结合蛋白与glp-1激动剂的组合来治疗或改善代谢病症的方法 |
| CA3071939A1 (en) | 2017-08-04 | 2019-02-07 | Ovid Therapeutics Inc. | Use of gaboxadol in the treatment of diabetes and related conditions |
| CA3078652A1 (en) | 2017-10-12 | 2019-04-18 | Novo Nordisk A/S | Semaglutide in medical therapy |
-
2018
- 2018-10-10 CA CA3078652A patent/CA3078652A1/en active Pending
- 2018-10-10 IL IL322969A patent/IL322969A/en unknown
- 2018-10-10 IL IL322968A patent/IL322968A/en unknown
- 2018-10-10 KR KR1020207012311A patent/KR20200069316A/ko active Pending
- 2018-10-10 CN CN202510086779.1A patent/CN120241968A/zh active Pending
- 2018-10-10 MX MX2020003049A patent/MX2020003049A/es unknown
- 2018-10-10 CN CN201880066425.9A patent/CN111212657A/zh not_active Withdrawn
- 2018-10-10 CN CN202411858188.3A patent/CN119950682A/zh active Pending
- 2018-10-10 CN CN202510084667.2A patent/CN119838000A/zh active Pending
- 2018-10-10 EP EP18788709.6A patent/EP3694538A1/en active Pending
- 2018-10-10 WO PCT/EP2018/077654 patent/WO2019072941A1/en not_active Ceased
- 2018-10-10 JP JP2020517328A patent/JP7148605B2/ja active Active
- 2018-10-10 BR BR112020006246-4A patent/BR112020006246A2/pt not_active Application Discontinuation
- 2018-10-10 SG SG11202002841PA patent/SG11202002841PA/en unknown
- 2018-10-10 MY MYPI2020001658A patent/MY204827A/en unknown
- 2018-10-10 AU AU2018348929A patent/AU2018348929B2/en active Active
- 2018-10-10 MA MA050358A patent/MA50358A/fr unknown
- 2018-10-12 TW TW107136028A patent/TWI842681B/zh active
-
2020
- 2020-03-19 MX MX2025002189A patent/MX2025002189A/es unknown
- 2020-03-19 MX MX2025002188A patent/MX2025002188A/es unknown
- 2020-03-20 IL IL273470A patent/IL273470A/en unknown
- 2020-03-27 PH PH12020550185A patent/PH12020550185A1/en unknown
- 2020-03-27 CL CL2020000812A patent/CL2020000812A1/es unknown
- 2020-04-09 US US16/844,552 patent/US12029779B2/en active Active
-
2022
- 2022-07-13 JP JP2022112446A patent/JP7475398B2/ja active Active
-
2024
- 2024-06-07 US US18/736,608 patent/US20240316159A1/en not_active Abandoned
- 2024-08-30 US US18/820,792 patent/US12295988B2/en active Active
-
2025
- 2025-04-09 US US19/174,121 patent/US12551536B2/en active Active
- 2025-04-22 ZA ZA2025/03388A patent/ZA202503388B/en unknown
- 2025-04-22 ZA ZA2025/03350A patent/ZA202503350B/en unknown
- 2025-04-22 ZA ZA2025/03387A patent/ZA202503387B/en unknown
-
2026
- 2026-01-29 US US19/463,848 patent/US20260232771A1/en active Pending
- 2026-07-17 AU AU2026206205A patent/AU2026206205A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202503387B (en) | Semaglutide in medical therapy | |
| MX2024013963A (es) | Un antagonista de il-4r util para el tratamiento o la prevencion del asma | |
| MX378273B (es) | Compuestos activos hacia bromodominios. | |
| MX2021008113A (es) | Composiciones farmaceuticas que comprenden un antagonista de il-4r para usarse en el tratamiento del asma. | |
| MX2018002990A (es) | Uso de la akkermansia pasteurizada para tratar trastornos metabolicos. | |
| PH12016502167A1 (en) | Hdl theraphy markers | |
| MX2021014242A (es) | Uso de linagliptina en terapia antidiabetica cardio- y renoprotectora. | |
| CL2014001865A1 (es) | Compuestos derivados de fosfatos; procedimiento de preparacion; composiciones farmaceuticas que los contienen y uso en el tratamiento del cancer. | |
| MX380252B (es) | Crenezumab para usarse en el tratamiento de enfermedad de alzheimer. | |
| MX2017002489A (es) | Agentes terapeuticos humanos. | |
| MX2018008640A (es) | Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]- decano. | |
| CY1119532T1 (el) | (s)-πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη | |
| CR20160529A (es) | Composiciones farmacéuticas para tratar enfermedades infecciosas | |
| TWD190452S (zh) | 口腔保健器具 | |
| ECSP16086232A (es) | (r) -pirlindole y sus sales farmacéuticamente aceptables para uso en medicina | |
| EA201590615A1 (ru) | Стимулирующие лактацию композиции на основе фосфатидилсерина | |
| SG10201903630UA (en) | Iminosugars useful for the treatment of viral diseases | |
| LT3609486T (lt) | Sarpogrelatas, skirtas naudoti žinduolių širdies ligų gydymo būdui | |
| EP3342406A4 (en) | USE OF DIHYDROXYACETONE IN THE MANUFACTURE OF ANTI-TUMOR MEDICAMENT | |
| EA201692164A1 (ru) | Лекарственное средство для лечения пациентов с тиннитусом | |
| EA201690709A1 (ru) | Применение одипарцила в лечении мукополисахаридоза | |
| AR095890A1 (es) | Uso de ácido trifluoroacético y sales del mismo para tratar la hipercolesterolemia | |
| EA201991866A1 (ru) | Комбинированная терапия | |
| FR3024718B1 (fr) | Plateau rotatif de repas combine s'etendant infiniment | |
| UA89076U (uk) | Застосування стоматологічної настойки "касдент" для лікування запальних захворювань ротової порожнини |